Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies
RegulatoryCRLNegative
AI Analysis
Summary
Unicycive Therapeutics received an FDA Complete Response Letter citing third-party manufacturing deficiencies, resulting in a 33.1% stock decline.
Outcome Details
FDA issued Complete Response Letter citing third-party manufacturing deficiencies
Importance:9/10
Sentiment:
-0.95
FDACRLmanufacturingstock_decline
Related Companies
Read the original article
Published by yahoo_finance on July 1, 2026 10:13 PM